| Authors: |
Sison-Young RL; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK., Lauschke VM; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, SE-171 77, Stockholm, Sweden., Johann E; Early Non-Clinical Safety, Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany., Alexandre E; KaLy-Cell, 20A rue du Général Leclerc, 67115, Plobsheim, France., Antherieu S; Université de Lille 2, EA 4483, Lille, France., Aerts H; Biologie Servier, 905 Rue de Saran, 45520, Gidy, France., Gerets HHJ; UCB BioPharma SPRL, Non-Clinical Development, Chemin du Foriest, 1420, Braine-l'Alleud, Belgium., Labbe G; Sanofi-Aventis Recherche and Développement, Drug Safety Evaluation, Alfortville, France., Hoët D; Sanofi-Aventis Recherche and Développement, Drug Safety Evaluation, Alfortville, France., Dorau M; Sanofi-Aventis Deutschland GmbH, R&D DSAR, Preclinical Safety FF, Industriepark Hoechst, Building H823, Room 104, 65926, Frankfurt am Main, Germany., Schofield CA; GSK, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK., Lovatt CA; GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire, SG12 0DP, UK., Holder JC; GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire, SG12 0DP, UK., Stahl SH; AstraZeneca, Innovative Medicines and Early Development, Drug Safety and Metabolism, ADME Transporters, Unit 310 - Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0FZ, UK., Richert L; KaLy-Cell, 20A rue du Général Leclerc, 67115, Plobsheim, France.; Université de Franche-Comté, EA 4267, 25030, Besançon, France., Kitteringham NR; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK., Jones RP; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.; North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Longmoor Lane, Liverpool, L9 7AL, UK., Elmasry M; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.; North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Longmoor Lane, Liverpool, L9 7AL, UK., Weaver RJ; Biologie Servier, 905 Rue de Saran, 45520, Gidy, France., Hewitt PG; Early Non-Clinical Safety, Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany., Ingelman-Sundberg M; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, SE-171 77, Stockholm, Sweden., Goldring CE; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK. chrissy@liverpool.ac.uk., Park BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK. |
